Sales of Biogen’s Alzheimer’s Drug Fall Short of Expectations October 20, 2021 Auto Bot Aduhelm (Drug), alzheimer's disease, Biogen Inc, Cleveland Clinic, Food and Drug Administration, Medicare, Vounatsos, Michel 0 The drug, Aduhelm, brought in $300,000 in revenue in its first full three months of availability. The company expects the drug to generate minimal revenue for the rest of the year.